GPS for nemluvio™

GALDERMA PATIENT SERVICES

Billing and Coding Guide

Commonly Used Codes for NEMLUVIO® for the Treatment of Adults With Prurigo Nodularis (PN)

Disclaimer: These codes are not an exhaustive list of all possible or required billing and coding options for NEMLUVIO and are not intended to provide reimbursement advice. The provider is responsible for ensuring accurate and appropriate diagnostic coding to reflect patient diagnosis and to obtain reimbursement. For additional guidance on coding, please refer to the Department of Health and Human Services Evaluation and Management Services Guide available at www.cms.gov.

ICD-10 Diagnosis Code for PN

ICD-10 codes are diagnostic codes used by health care providers (HCPs) to classify and code all diagnoses, symptoms, and procedures for claims processing.[1]

Coding is a clinical decision; ensure you are coding to the highest level of specificity. The code shown below is only a suggestion and may vary by patient.

ICD-10 Code[2]	Description[2]
L28.1	Prurigo nodularis

ICD-10, International Classification of Diseases, Tenth Revision.

Please see Important Safety Information on page 3 and accompanying Prescribing Information or click here for full Prescribing Information.

GALDERMA

EST. 1981

NDC for NEMLUVIO

An NDC is a unique, 3-segment number that serves as a universal product identifier for a drug.[3]

NDCs[4]	Description[4]	Dosage Strength[4]
10-digit code: 0299-6220-15 11-digit code: **0**0299-6220-15	Prefilled pen (pack of 1 pen)	30 mg/0.49 mL

Electronic data exchange standards usually require the use of an 11-digit NDC. To convert a 10-digit NDC to an 11-digit NDC, a leading zero is added within the sequence of numbers. In this case, the **boldface** zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary.

Specialty Distributor

NEMLUVIO is available for physician offices to order through Cencora. Please note that Cencora is our exclusive distribution partner for physicians utilizing the buy & bill model **only**. To set up an account with Cencora, please call Cencora customer service at 1-800-746-6273.

Cencora Ordering Information			
Phone Number	**Fax**	**Email**	**Website**
1-800-746-6273	1-800-547-9413	service@asdhealthcare.com	www.asdhealthcare.com/contact-us

For support in person or over the phone, call a Field Access Manager or the Galderma Patient Services (GPS) for NEMLUVIO at 855-NEMLUVIO.

NDC, National Drug Code.

Please see Important Safety Information on page 3 and accompanying Prescribing Information or click here for full Prescribing Information.

GPS for nemluvio™

GALDERMA PATIENT SERVICES

IMPORTANT SAFETY INFORMATION

Indication: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis. **Contraindication:** Known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO. **Warnings/Precautions:** Hypersensitivity reactions have been reported with NEMLUVIO use. If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO. **Adverse Events:** Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit *www.fda.gov/medwatch* or call 1-800-FDA-1088.

Please see accompanying Prescribing Information or click here for full Prescribing Information.

References: 1. American Medical Association. ICD-10. Accessed March 15, 2024. https://www.ama-assn.org/topics/icd-10 **2.** Centers for Medicare & Medicaid Services. 2024 ICD-10-CM. Accessed March 11, 2024. https://www.cms.gov/medicare/coding-billing/icd-10-codes/2024-icd-10-cm **3.** United States Food and Drug Administration. National Drug Code database background information. Accessed March 11, 2024. https://www.fda.gov/drugs/development-approval-process-drugs/national-drug-code-database-background-information **4.** NEMLUVIO. Prescribing Information. Galderma Laboratories, L.P.; August 2024.

GALDERMA

EST. 1981